Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer
Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer

NCT04801186

CompletedN/A

Sponsor: AstraZeneca

Conditions: Metastatic Castration-resistant Prostates Cancer

Countries: Colombia, Egypt, India, Peru, Saudi Arabia, South Korea, Turkey (Türkiye), United Arab Emirates

This is a multi-country, multi-centre, retrospective, non-interventional cohort study planned to include patients diagnosed with mCRPC between 01 January 2016 and 31 December 2018, who have received at least 1 line of treatment (LOT) in the mCRPC setting, and have 12 months of follow-up data available.

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Male patients ≥18 years of age OR legal age of being an adult in the country as per local regulations 2. Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations 3. Patients with a diagnosis of metastatic (stage IV) mCRPC, confirmed by either biopsy of a metastatic tumour site or by history of biopsy-proven localized disease and evidence of metastatic disease on imaging studies (which is clearly noted in hospital/clinical records) and progression on ADT alone between 01 January 2016 and 31 December 2018 4. Availability of medical records at the participating site reflecting at least one LOT received in the mCRPC setting and 12 months of follow-up from the index date (unless the patient died or was lost to follow-up within the first 12 months after diagnosis)

Exclusion Criteria:

-1. Patients with a concomitant cancer at the time of diagnosis of mCRPC or those who are treated with any anti-cancer therapy indicated for other cancers within 6 months of diagnosis of mCRPC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms.

2\. Patients unable to give an informed consent (unless a waiver is granted)
Locations (30)
  • Valledupar, Colombia
  • Alexandria, Egypt
  • Cairo, Egypt
  • Cairo, Egypt
  • Cairo, Egypt
  • Cairo, Egypt
  • Luxor, Egypt
  • Ahmedabad, Gujarat, India
  • Faridabad, Haryana, India
  • Srinagar, Jammu and Kashmir, India
  • Bengaluru, Karnataka, India
  • Mumbai, Maharashtra, India
  • New Delhi, National Capital Territory of Delhi, India
  • New Delhi, National Capital Territory of Delhi, India
  • New Delhi, National Capital Territory of Delhi, India
  • Bhubaneswar, Odisha, India
  • Secundrabad, Telangana, India
  • Howrah, West Bengal, India
  • Lima, Peru
  • Riyadh, Saudi Arabia
  • Riyadh, Saudi Arabia
  • Goyang-si, Gyeonggi-do, South Korea
  • Seongnam-si, Gyeonggi-do, South Korea
  • Gangnam-gu, Seoul, South Korea
  • Jongno-gu, Seoul, South Korea
  • Seocho-gu, Seoul, South Korea
  • Seodaemun-gu, Seoul, South Korea
  • Turkey, Turkey, Turkey (Türkiye)
  • Alain, United Arab Emirates, United Arab Emirates
  • Dubai, United Arab Emirates